The FDA approved the Wegovy pill (oral semaglutide 25 mg, once daily) in late 2025, and it launched in the US in early January 2026
In none of those instances has the board demonstrated how these excessive regulations make patients safer. A threat to patient access The proposed regulations, which allow for very limited exceptions, threaten to end patient access to all 47 Category 1 Sterile Compounds despite the fact that they are federally allowed under the FDAs interim policy
These drugs are not just reshaping waistlines, they are reshaping mindsets, and the effects are measurable
Patients should be educated on recognising and managing hypoglycaemia, and dose adjustments of concomitant diabetes medications may be necessary
GLP-1 receptor agonists and their role in metabolism
The website operator has a legitimate interest in the technically error-free presentation and optimization of his/her website - for this purpose, the server log files must be collected